Story perspectives

FDA Committee Approves Pharmacy Compounding of Six Peptides, $2-3B Opportunity

7/26/2026

Summary

Story summary

Secretary Robert F. Kennedy Jr. convened the FDA advisory committee, which on July 23-24, 2026 voted to permit pharmacies to produce six of seven peptides.
The vote split by appointment date, with April-May appointees supporting and members opposing.
FDA staff warned the peptides lack safety and efficacy data, noting the agency cannot set guardrails.
Analysts estimate legalizing peptide compounding could generate a $2-$3 billion market for firms like Hims & Hers.

1 of 1

Story summary

Secretary Robert F. Kennedy Jr. convened the FDA advisory committee, which on July 23-24, 2026 voted to permit pharmacies to produce six of seven peptides.
The vote split by appointment date, with April-May appointees supporting and members opposing.
FDA staff warned the peptides lack safety and efficacy data, noting the agency cannot set guardrails.
Analysts estimate legalizing peptide compounding could generate a $2-$3 billion market for firms like Hims & Hers.